GC Green Cross Completes Phase 2 Clinical Trial of COVID-19 Plasma Therapy

[Image source=Yonhap News]

[Asia Economy Reporter Cho Hyun-ui] The Phase 2 clinical trial of the novel coronavirus disease (COVID-19) plasma treatment developed by GC Green Cross has been completed. GC Green Cross plans to promptly derive Phase 2 clinical data and apply for conditional approval.

According to the pharmaceutical industry on the 6th, GC Green Cross completed patient enrollment and dosing for the Phase 2 clinical trial of the COVID-19 plasma treatment 'GC5131A' on December 31 of last year.

GC Green Cross has been developing a treatment made by fractionating antibodies with immunogenicity from the plasma of recovered COVID-19 patients and conducting Phase 2 clinical trials targeting high-risk patients. The company aims to complete data derivation within the first quarter of this year.

GC5131A is already being prescribed to some patients in medical settings. From October last year to the 5th of this month, it has obtained a total of 30 approvals for therapeutic use from the Ministry of Food and Drug Safety.

To respond to the increasing demand in medical settings, GC Green Cross completed the third production of 240 liters on November 30. All of this is supplied to medical institutions intending to use it for patient treatment purposes.

This content was produced with the assistance of AI translation services.